Compounds > pyrazinamide

pyrazinamide and lopinavir

pyrazinamide has been researched along with lopinavir in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ1
de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J1
Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H1

Other Studies

5 other study(ies) available for pyrazinamide and lopinavir

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Curve; Biological Availability; Coinfection; Female; HIV Infections; HIV-1; Humans; Isoniazid; Lopinavir; Male; Models, Statistical; Mycobacterium tuberculosis; Outpatients; Prospective Studies; Pyrazinamide; Rifampin; Ritonavir; South Africa; Tuberculosis, Pulmonary

2016
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:2

    Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug Interactions; Ethambutol; Female; HIV; HIV Infections; Humans; Isoniazid; Lopinavir; Male; Models, Statistical; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary

2018
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
    PLoS medicine, 2023, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis

2023